Abstract
Background: Evidence accumulates that the neuropeptide oxytocin plays an important role in mediating social interaction among humans and that a dysfunction in oxytocin-modulated brain mechanisms might lie at the core of disturbed social behavior in neuropsychiatric disease. Explanatory models suggest that oxytocin guides social approach and avoidance by modulating the perceived salience of socially meaningful cues. Animal data point toward the ventral tegmental area (VTA) as the brain site where this modulation takes place. Methods: We used functional magnetic resonance imaging and a social incentive delay task to test the hypothesis that oxytocin modulates the neural processing of socially relevant cues in the VTA, hereby facilitating behavioral response. Twenty-eight nulliparous women (not taking any hormones) received intranasal oxytocin or placebo in a double-blind randomized clinical trial with a parallel-group design. Results: Oxytocin significantly enhanced VTA activation in response to cues signaling social reward (friendly face) or social punishment (angry face). Oxytocin effects on behavioral performance were modulated by individual differences in sociability with enhanced performance in women scoring low but decreased performance in women scoring high on self-reported measures of agreeableness. Conclusions: Our data provide evidence that the VTA is the human brain site where oxytocin attaches salience to socially relevant cues. This mechanism might play an important role in triggering motivation to react at the prospect of social reward or punishment.
| Original language | English |
|---|---|
| Journal | Biological Psychiatry |
| Volume | 74 |
| Issue number | 3 |
| Pages (from-to) | 172-179 |
| Number of pages | 8 |
| ISSN | 0006-3223 |
| DOIs | |
| Publication status | Published - 01.08.2013 |
Funding
Dr. Gründer has served as a consultant for Bristol-Myers Squibb (New York, New York), Cheplapharm (Greifswald, Germany), Eli Lilly (Indianapolis, Indiana), Forest Laboratories (New York, New York), Lundbeck (Copenhagen, Denmark), Otsuka (Rockville, Maryland), and Servier (Paris, France). He has served on the Speakers’ bureau of Bristol-Myers Squibb, Eli Lilly, Otsuka, Roche (Basel, Switzerland), and Servier (Paris, France). He has received grant support from Alkermes, Bristol-Myers Squibb, Eli Lilly, and Johnson & Johnson. He is co-founder of Pharma Image-Molecular Imaging Technologies GmbH, Düsseldorf. All other authors report no biomedical financial interests or potential conflicts of interest. This study was carried out at the Department of Psychiatry at RWTH Aachen University, Germany, and was supported by the START-funding program of the RWTH Aachen Medical Faculty and a research fellowship of the German Research Foundation (SP1274/1-1) to KNS. We thank Brian Knutson for helpful comments on an earlier version of this manuscript.
Research Areas and Centers
- Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)